|Bid||46.50 x 1100|
|Ask||46.90 x 1000|
|Day's Range||45.27 - 50.49|
|52 Week Range||3.54 - 61.50|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.20|
There are a couple of easy ways to determine if a publicly traded company has become the center of attention. You can look at its average daily trading volume or look up the company's name on Google Trends.
First things first: Not every company involved in developing diagnostic tests, treatments, or vaccines for COVID-19 will be a winner over the long term. After reviewing the quite lengthy list of companies with COVID-19 programs, I selected three that I think have really good chances of delivering strong returns over the next five years. Goldman Sachs recently downgraded Abbott Labs (NYSE: ABT) to a sell.
If you want to bet on cutting-edge vaccine development but don't want the risk that comes with investing in a clinical-stage biotech company, you can opt for Pfizer (NYSE: PFE). The big pharma company partnered with BioNTech (NASDAQ: BNTX) to advance the German biotech company's investigational messenger RNA (mRNA) coronavirus vaccine program. Pfizer and BioNTech have started human testing later than rivals such as Moderna (NASDAQ: MRNA) -- also working on an mRNA vaccine -- or Inovio Pharmaceuticals (NASDAQ: INO).
The Trump administration picked out five companies it believes are most likely to produce 2020’s holy grail – a vaccine for the coronavirus. Unfortunately, Novavax (NVAX) was not on the list.Although the White House didn’t disclose what lay behind the choices, 5-star B.Riley FBR analyst Mayank Mamtani provided some possible explanations.3 of the choices already have clinical studies in various degrees of progress (Moderna, AstraZeneca/Oxford University and Pfizer/BioNTech), whilst Novavax only began enrollment late last month. This implies to Mamtani that “speed to market entry” could be a major factor in the decision-making process.Whilst “risk diversification and cost sharing,” and a preference for large companies (Johnson & Johnson, Merck) with the necessary balance sheet required to conduct the extensive and pricey vaccine development and manufacturing may also be contributing factors.Even so, while those reasonings might explain the smaller player’s omission, Mamtani maintains Novavax should be added to the list.Mamtani said, “We remain encouraged by the de-risked nature of NVAX's vaccine candidate, on the basis of the most extensive preclinical data generated to date, and now reviewed closely by the global scientific community residing with CEPI, WHO, and SII, as well as U.S. agencies such as CDC, NIH-NIAID, and BARDA. We believe adding NVAX's NVX-CoV2373 on the basis of its proprietary adjuvanted recombinant nanoparticle platform could further help diversify development risk as well as tap into a relatively clearer path to market and manufacturing scale-up that NVAX has made tangible progress on recently…”To this end, Mamtani reiterated a Buy on NVAX and has a $74 price target, indicating the potential for 60% upside over the next year. (To watch Mamtani’s track record, click here)All other 4 analysts to post a Novavax review over the last 3 months recommend the stock a Buy, too. A Strong Buy consensus rating is accompanied by a $49.20 price target, implying room for an 11% uptick in the months ahead. (See Novavax stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Wall Street surged on Friday after a strikingly upbeat May jobs report unexpectedly provided the clearest evidence yet that the U.S. economy is headed for a quicker-than-anticipated recovery. The Nasdaq breached its all-time closing high reached in February but pared its gains to end the session a hair's breadth below it. All three major U.S. stock indexes advanced 2% or more.
Wall Street surged on Friday after a strikingly upbeat May jobs report unexpectedly provided the clearest evidence yet that the U.S. economy is headed for a quicker-than-anticipated recovery. The Nasdaq breached its all-time closing high reached in February but pared its gains to end the session just below it. The S&P 500 and the Dow are both well within 10% of overtaking their record closing levels.
Wall Street surged on Friday, and the Nasdaq was on course to set a new record closing high after the May jobs provided an astounding upside surprise and the clearest evidence yet that the U.S. economy is bouncing back sooner than expected from pandemic-related lockdowns. The Nasdaq is set to be the first among the three major U.S. stock indexes to reclaim all-time highs reached in February. The S&P 500 and the Dow are now within 6% and 8% of overtaking their record closing levels.
A stunning U.S. jobs report on Friday put the Nasdaq within striking distance of its record high as investors flocked back to riskier assets on hopes of a swift economic rebound from the coronavirus-driven slump. The blue-chip Dow Jones index added 1,000 points, briefly hitting a level not seen since early March, while the S&P 500 is less than 1% away from turning positive on the year.
Novavax, Inc. (NASDAQ: NVAX) is landing financing deals that could help to successfully develop a vaccine for SARS-CoV, the virus that causes COVID-19.Novavax's Defense Department Funding The Gaithersburg, Maryland-based biotech said late Thursday that it has been granted funding of up to $60 million by the Department of Defense for manufacturing several components of the vaccine codenamed NVX-CoV2373 in the U.S.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Novavax Analyst: Positive NanoFlu Readout Could Have Driven Increased Conviction The accent on domestic manufacturing is probably due to security reasons, Cantor Fitzgerald analyst Charles Duncan said in a note.Novavax's vaccine consists of stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes its proprietary Matrix M adjuvant.The analyst said he expected funding from government organizations, although Novavax was not part of the "unofficial" list of five finalists for the White House's "Operation Warp Speed."The agreement signals conviction in Novavax's recombinant nanoparticle platform and its potential to deliver an efficacious vaccine for COVID-19, probably due to the recent positive Phase 3 readout for its NanoFlu vaccine, he said. Cantor has an Overweight rating and $45 price target for Novavax shares.In mid-May, the company received an incremental $384 million in funding from the Coalition for Epidemic Preparedness Innovations for its vaccine program."We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide," Novavax CEO Stanley Erck said in a statement. What's Next For Novavax Novavax said as part of the contract it will work with a U.S.-based biologics CDMO to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine to be used in Phase 2/3 studies and/or under an Emergency Use Authorization if one is approved by the FDA.It will also work with U.S.-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine.The company is conducting a Phase 1 study in healthy volunteers, with preliminary immunogenicity and safety data due in July."Forthcoming data this summer should provide a gauge of possibilities and probabilities for moving forward," said Cantor's Duncan. NVAX Price Action Novavax shares were up 2.31% at $45.69 at the time of publication Friday. Related Links:The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets 0M Bid Coronavirus Vaccine Frontrunner Moderna Appoints Former Amgen Executive As CFO Latest Ratings for NVAX DateFirmActionFromTo Jun 2020JP MorganUpgradesUnderweightNeutral May 2020B. Riley FBRMaintainsBuy May 2020B. Riley FBRMaintainsBuy View More Analyst Ratings for NVAX View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study * Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Novavax (NASDAQ: NVAX) soared 153.9% in May, according to data provided by S&P Global Market Intelligence, after the company announced more than $300 million in funding for its coronavirus vaccine program and said it initiated its clinical trial. Novavax said the Coalition for Epidemic Preparedness Innovations (CEPI) will invest as much as $384 million in the project after earlier investing $4 million. The company also said it has enrolled the first participants in the phase 1/2 clinical trial of its coronavirus vaccine.
U.S. stock indexes jumped on Friday, with the Nasdaq Composite less than 1% away from a record high, on hopes of a faster economic rebound from a coronavirus-led slump after data showed surprise job additions in May. At 11:09 a.m. ET, the Dow Jones Industrial Average was up 868.73 points, or 3.31%, at 27,150.55, the S&P 500 was up 81.85 points, or 2.63%, at 3,194.20 and the Nasdaq Composite was up 183.41 points, or 1.91%, at 9,799.22.
U.S. stock indexes jumped on Friday, with the Nasdaq Composite less than 1% away from a record high, after a closely watched report showed surprise job additions in May, lending weight to hopes of a faster economic rebound from a coronavirus-led slump. Data from the Labor Department showed nonfarm payrolls rose by 2.509 million jobs last month after a record plunge of 20.687 million in April, and the unemployment rate unexpectedly fell to 13.3% in May from 14.7% in April. "The unemployment rate was likely to peak in May and then get better from there, but it looks as though it might have peaked in April, which is a very positive development for the economy."
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
In return for up to $60 million in funding, the biotech will deliver 10 million doses of NVX-CoV2373 to the military in 2020.
What happened Shares of the developmental-stage vaccine company Novavax (NASDAQ: NVAX) are gearing up for another strong session today. In premarket action Friday morning, the biotech's shares jumped by as much as 14.
Shares of Novavax Inc. soared 14% in premarket trading Friday, after the biotechnology company said it was awarded a contract by the U.S. Department of Defense to manufacture its NVX‑CoV2373 COVID-19 vaccine candidate. The DoD has agreed to provide Novavax with up to $60 million to fund the production of several components of the potential vaccine in the U.S. As part of the contract, announced late Thursday, Novavax agreed to delivery in 2020 10 million doses of NVX‑CoV2373 for DoD that could be used in phase 2/3 clinical trials, or under an Emergency Use Authorization if approved by the Food and Drug Administration. On Friday, J.P. Morgan analyst analyst Eric Joseph upgraded Novavax's stock to neutral from underweight, while reiterating his $46 stock price target, saying current share price levels reflect the potential promise for the COVID-19 vaccine program. The stock has rocketed more than 11-fold year to date through Thursday (up 1,022%), while the S&P 500 has slipped 3.7%.
Friday's report from the Labor Department is likely to show the U.S. unemployment rate shooting up to almost 20% in May, a new post-World War Two record, but investors have so far shrugged off dire data on hopes that an easing of coronavirus-led lockdowns would revive business activity. The Nasdaq 100 became the first U.S. equity index on Thursday to reclaim its all-time high, with the rebound driven partly by tech-related firms including Amazon.com Inc and Netflix Inc. The Nasdaq Composite, which is more closely watched than the Nasdaq 100, is just about 2% below its own record high, while the S&P 500 and Dow Jones indexes are 8% and 11% below their respective all-time highs.
Biotech Novavax (NVAX) has announced that the U.S. Department of Defense (DoD) will provide up to $60 million in funding to assist with the manufacturing of NVX‑CoV2373, Novavax’s COVID-19 vaccine candidate. Shares are currently surging 15% in Friday’s pre-market trading.The news comes after the company failed to make the cut as one of the five COVID-19 vaccine finalists selected for the Trump administration’s Operation Warp Speed project.NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. It consists of a stable, prefusion protein antigen made using the company’s proprietary nanoparticle technology and Matrix‑M adjuvant.According to Novavax, the funding will help support its production of several components of the vaccine that will be manufactured in the U.S.The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA.“Importantly, this award will allow Novavax to significantly expand its U.S. production capacity of NVX-CoV2373, a critical step in our ability to provide vaccine support to the COVID-19 pandemic” said Stanley C. Erck, CEO of Novavax.Novavax will work with a U.S.-based biologics contract development manufacturing organization (CDMO) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine.And the company will also collaborate with U.S.-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine, Novavax said.In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. A Phase 1 clinical trial began in May 2020, with preliminary immunogenicity and safety results expected in July 2020.The Coalition for Epidemic Preparedness Innovations (CEPI) is also investing up to $388 million of funding to advance clinical development of NVX‑CoV2373.Year-to-date shares in NVAX have exploded by a jaw-dropping 1,022%- and analysts are bullish on the stock’s potential. Novavax scores a Strong Buy Street consensus with five back-to-back recent buy ratings. The average analyst price target stands at $49 (10% upside potential). (See Novavax stock analysis on TipRanks).“We remain encouraged by the de-risked nature of NVAX’s vaccine candidate, on the basis of the most extensive preclinical data generated to date” commented B.Riley FBR analyst Mayank Mamtani on June 3.The analyst reiterated a buy rating and $61 price target adding “We believe adding NVAX’s NVX-CoV2373 on the basis of its proprietary adjuvanted recombinant nanoparticle platform could further help diversify development risk as well as tap into a relatively clearer path to market and manufacturing scale-up.”Related News: Novavax Spikes 31% on $384 Million Cash Injection for Vaccine Production Moderna’s (MRNA) Stock Will Surge 80% From Current Levels, Says Analyst Think Novavax Has Surged Enough for Now? Think Again, Says 5-Star Analyst More recent articles from Smarter Analyst: * Micron's Growth Story Remains Intact, Says Analyst * Aurora Cannabis (ACB): The Stock Is Too Hot on U.S. CBD Entry * Billionaire Jim Simons Snaps Up These 3 Penny Stocks * Facebook To Start Labeling State-Controlled Media Ahead of US Elections
Novavax Inc said on Thursday the U.S. Department of Defense (DoD) will give the late-stage biotech company up to $60 million to fund the manufacturing of its experimental COVID-19 vaccine. The U.S.-based company said the deal includes the delivery of 10 million doses of its COVID-19 vaccine - NVX-CoV2373 - to the DoD this year. The announcement of Novavax's vaccine trial came last month as drugmakers pause clinical trials on drugs for other ailments to focus on COVID-19, the illness caused by the novel coronavirus that has resulted in more than 386,379 deaths globally.
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.
(Bloomberg) -- Don’t give up hope for Novavax Inc. and Inovio Pharmaceuticals Inc., Wall Street analysts said after the two failed to appear on a Trump administration list of Covid-19 vaccine developers picked for Operation Warp Speed.The pair slid more than 10% on Wednesday following a New York Times report saying that the White House’s list included larger drugmakers such as AstraZeneca PLC, Johnson & Johnson, Merck & Co. and Pfizer Inc., but not the pair of small-caps.Bloomberg reporting shows that two other, as yet unnamed, companies have also been selected for the U.S. government’s effort. An official announcement is expected within weeks.One analyst thought Inovio must be one of the missing finalists from the White House’s effort. “INO-4800 is more-than-likely on the short list of remaining vaccine candidates,” Stifel’s Stephen Willey wrote, pointing to safety and immunogenicity results expected by the end of the month as well as Inovio’s “competitive advantages.” The Plymouth Meeting, Pennsylvania-based company’s experimental vaccine, INO-4800, uses part of the virus’s DNA to trigger an immune response.“WARP Speed finalists may not be final” and the initial list may be short-sighted, Cantor Fitzgerald analyst Charles Duncan said. “Show me the data,” he said, noting the vaccine developers mentioned were “high-profile, large pharma candidates, all of which lack significant clinical experience.”Duncan expects that different approaches to developing an immunization against Covid-19 will be needed and saw both Inovio and Novavax’s candidates as good options, though neither has yet to commercialize a product. He gives Inovio and Novavax buy-equivalent ratings.The two U.S.-based biotechs are each working on one of the 10 vaccines for Covid-19 currently being tested in humans, according to the World Health Organization. More than 120 others are being tested in animals. Also in the clinical stages of vaccine development, but not mentioned in the Bloomberg or N.Y.Times reports, are Chinese vaccine developers Sinovac Biotech Ltd., CanSino Biologics Inc. and SinoPharm Group Co., all three of whom are conducting human trials of vaccines.Moderna Inc., another unproven vaccine developer that’s working on an RNA-based immunization, was selected. The Cambridge, Massachusetts-based biotech has been working with the National Institutes of Health since the start of the pandemic and is already backed by more than $400 million in federal funding. One problem with Moderna’s and other rival’s methods will be cold storage and finding enough facilities to house their vaccines. That’s not a problem for Novavax’s protein based approach or Inovio’s DNA-based platform, Cantor’s Duncan said.Novavax is not without backers. The biotech secured $388 million in May, the single largest grant from the Coalition for Epidemic Preparedness Innovations (CEPI) at the time. Inovio has received $17 million from the Oslo-based group.Another blow to confidence in untested vaccine developers came on Thursday after AstraZeneca secured $750 million from CEPI and Gavi, the Vaccine Alliance, a non-profit organization.Prominent makers of vaccines such as Sanofi and GlaxoSmithKline Plc, were also notably absent from the White House list. Operation Warp Speed is headed up by Moncef Slaoui, a former Glaxo executive.Inovio fell as much as 4.3% Thursday. Novavax rose as much as 5.5% before paring most of those gains.Inovio and Novavax didn’t immediately respond to emails seeking comment.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Novavax is well ahead in clinical testing than two of the White House's COVID-19 vaccine finalists.
The global economy is slowly emerging from lockdowns enacted to beat back the coronavirus. The pandemic isn't going anywhere, however, and hopes of a return to a semblance of normal rest heavily on the speedy development of vaccines against SARS-CoV-2, the virus that causes COVID-19.Fast-Tracking Vaccine Programs Vaccine development typically takes about 10-15 years, as it has to go through the same general pathway as that of drugs and biologics. With the advent of new classes of vaccines such as DNA and mRNA vaccines, development timelines could be tightened relative to traditional vaccines.Pandemics in recent history such as the MERS and SARS, also caused by coronaviruses, set in motion several R&D programs that have come in handy in today's scenario, as the new coronavirus shares 80% of its traits with its predecessors.Public-private partnerships have been forged to expedite vaccine programs. In mid-April, the National Institutes of Health announced a co-operative framework involving several biopharma companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the CDC, the FDA and the European Medicines Agency for expediting drug and vaccine research. Federal agencies have extended funding for companies with promising vaccine candidates in their pipeline, and this has given them the freedom to focus on research without having to worry about finances.The U.S. government recently launched the "Operation Warp Speed" project, which has among its objectives ensuring the availability of substantial quantities of a safe and effective vaccine for Americans by January 2021.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.US Government Backs 5 Vaccine Candidates In order to narrow the focus on the most deserving vaccine candidates, the Trump administration has shortlisted five from a crowded field and will likely make an announcement in this regard in the next few weeks, the New York Times reported.The shortlisted companies are, according to the Times: * Moderna Inc (NASDAQ: MRNA) * The Oxford University/AstraZeneca plc (NYSE: AZN) combination * Johnson & Johnson (NYSE: JNJ) * Merck & Co., Inc. (NYSE: MRK) * Pfizer Inc. (NYSE: PFE)Incidentally, Merck was a late entrant in the vaccine race, with the pharma giant announcing partnerships and deals to develop COVID-19 treatments and vaccines only recently.10 Vaccine Candidates In Clinics, 123 More In Labs A June 2 document from the World Health Organization showed that 10 vaccine candidates are in the clinics and 123 more are being evaluated in animal studies. Among the 10 vaccine candidates being tested in human studies, five are developed by Chinese firms or institutions. Here's an update on the 10 vaccines in the clinics:University Of Oxford/AstraZeneca The vaccine developed by the University of Oxford in collaboration with AstraZeneca was codenamed ChAdOx1 nCoV-19, a weakened version of a common cold virus that causes infections in chimpanzees.It has been genetically modified to make to prevent it from replicating in humans. After the university tied up with AstraZeneca, the vaccine candidate was renamed as AZD1222. AZD1222 is in a Phase 2/3 trial, with the university enrolling participants for the study in late May.Results from an ongoing Phase 1/2 trial could be available in mid-June; a university official was quoted as saying mid-May. AstraZeneca has received over $1 billion in BARDA funding for the development, production and delivery of the vaccine starting this fall.In late May, Adrian Hill, one of the lead investigators of the vaccine program, suggested the vaccine has only a 50% chance of succeeding, as the viral incidence receded in the community.Moderna Moderna, which is collaborating with NIAID for developing an mRNA vaccine, codenamed mRNA-1273, said recently it has dosed the first participant in a Phase 2 trial. The company also released interim data for its vaccine candidate from a NIAID-sponsored Phase 1 study, which showed dose-dependent increases in immunogenicity between prime and boost within the 25-microgram and 100-microgram dose levels. Moderna has prepped for scaling by forming an alliance with Swiss CDMO Lonza.See also: Inovio Analyst Watches Coronavirus Play 'From The Sidelines'CanSino Biological Inc./Beijing Institute of Biotechnology CanSino, which was the first to begin vaccine testing, announced last week the publication of Phase 1 data of its vaccine candidate Ad5 that showed most people developed immune responses.Yet he number of people developing neutralizing antibodies -- the ones that count for preventing infection -- was 75% among those who received the high dose and 50% among those who received the medium or low dose.A Phase 2 study of Ad5 was started in April and is underway. Ad5 is a genetically engineered adenovirus that delivers the gene encoding the spike protein of the SARS-CoV-2 into human cells.Wuhan Institute of Biological Products/Sinopharm The combo's vaccine candidate entered Phase 2 trials April 24, according to Xinhua. The Phase 1 trial is ongoing, the report said at that time. Sinopharm, one of the partners, seemed to suggest it will take one year of evaluation to determine the efficacy and safety of the inactivated vaccine candidate.Sinovac Sinovac, which began working on an inactivated vaccine candidate in January, said recently it is 99% confident in its vaccine candidate, codenamed CoronaVac. The candidate is in a Phase 1/2 trial. The company recently received $15 million in funding from private investors in lieu of a stake in the company.Novavax Novavax, Inc. (NASDAQ: NVAX) identified its vaccine candidate, codenamed NVX-CoV2373, in early April. The vaccine candidate is a stable prefusion protein made using the company's proprietary nanoparticle technology, with Matrix-M adjuvant incorporated to enhance the immunity response of the vaccine.The company said May 25 it enrolled the first participant in the Phase 1 portion of a Phase 1/2 study it has initiated, with results from the Phase 1 portion expected in July. In mid-May, the company announced an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations. On Wednesday, AGC Biologics said it has been tasked with manufacturing Matrix-M adjuvant by Novavax.Beijing Institute Of Biological Products/Sinopharm State-affiliated Beijing Institute of Biological Products, which is developing an inactivated vaccine in a Phase 1/2 trial, has started the Phase 2 trial, a post on the WeChat account of the Chinese state-owned Assets Supervision and Administration Commission said. Pfizer/BioNTech Pfizer is collaborating with German biopharma BioNTech SE - ADR (NASDAQ: BNTX) for vaccine development. BioNTech is evaluating four vaccine candidates in its BNT162 program. These are mRNA vaccines combined with a lipid nanoparticle formulation. BNT162 is being tested in separate Phase 1/2 trials in Europe and the U.S. Pfizer will be vested with the responsibility of scaling up at risk.Institute Of Medical Biology, Chinese Academy Of Medical Sciences In mid-May, the institute received approval for commencing a Phase 1 study.Inovio Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine codenamed INO-4800, said in its May 11 earnings release it has completed enrollment in a Phase 1 study.It anticipates commencing a Phase 2/3 efficacy trial in summer, subject to regulatory approval. Inovio has received funding from the CEPI as well as the Bill & Melinda Gates Foundation.Among others, J&J, which has identified a lead vaccine candidate, plans a clinical study by September. The company expects the first batches of a vaccine to be available for emergency use authorization by early 2021.Several other companies are also in the fray, including Sorrento Therapeutics Inc (NASDAQ: SRNE), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY).Related Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley See more from Benzinga * The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study * The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To 0M In Biotechs * Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
One of the country’s top COVID-19 experts made some discouraging comments regarding a potential vaccine for the coronavirus.
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.